How to Cite
Abstract
There are described the results of clinical and immunological efficacy assessment of active specific immunotherapy with autologous immature dendritic cells (DC) combined with photodynamic therapy (PDT) and cyclophosphamide (C) in disseminated melanoma patients, resistant to standard therapy. 27 patients treated in the N.N. Petrov Research Institute of Oncology were included in the study from 2007 till 2016. Immunotherapy was conducted in a 21-day cycles. Therapy included following steps: 1) preparation of individual vaccine preparation from bone-marrow derived DC with immune phenotype CD34-/CD14VCD1a+/CD83VCD80-/+/CD86-/+/HLA-DR+; 2) Intramuscular 300 mg C injection in day 1 of treatment cycle for elimination T-lymphocytes with immunosuppressing activity; 3) PDT with chlorin salts at day 4 six hours before start of vaccinotherapy; 4) Daily intralesional injections of DC vatccine in irradiated lesions in the dose 1х106 DC cells/ kg. Clinical and immunological efficacy was assessed in 27 patients. Fourteen (52%) patients received 1-2 cycles of therapy, 13(48%) received 3 or more cycles. No complete response was seen. Partial response (RECIST 1.1) was found in 2 (7,4%) patients, stable disease in 8 (29,6%) patients. Seventeen (63%) patients progressed. Median time to progression (TTP) was 2.5 month, median overall survival (OS) 8.4 month. One-year survival was 5% and 37% for TTP and OS, respectively. No adverse events (AE) of grade 4-5 (CTC AE v4) were seen. Grade 3 fever was registered in 4% of patients. Grade 1-2 AE were found in 54% of patients. Immunologic assessment revealed significant decline of immunoregulatory index (CD/ CD8) caused by prevalence of cytotoxic T-lymphocytes in peripheral blood of responding patients (patients with clinical benefit). Tendency for elevation of absolute number of activates T-helpers and cytotoxic T-lymphocytes together with low T-regulatory cells concentration was also found. Combination therapy using immunomodulatory effects of C, PDT and DC vaccine in 21-day treatment cycles produce promising activity and favorable toxicity profile in heavily pretreated disseminated melanoma patients.
References
Балдуева И.А., Новик А.В., Нехаева Т.Л. и соавт. Успехи и перспективы клеточной иммунотерапии метастатической меланомы кожи // Злокачественные опухоли. - 2015. - № 4. - С. 19-19.
Балдуева И.А., Моисеенко В.М., Гельфонд М.Л. и соавт. Разработка вакцины на основе костномозговых предшественников дендритных клеток (ДК), сенсибилизированных фотомодифицированной опухолью для лечения больных с диссеминированной меланомой кожи // Мед. иммунол. - 2011. - Т. 13. - С. 447.
Борунова А.А., Чкадуа Г.З., Заботина Т.Н., Кадагидзе З.Г. Изучение популяции CD16 лимфоцитов у онкологических больных на фоне вакцинотерапии // Мед. иммунол. - 2006. - Т. 8. - № 2-3. - С. 334.
Кадагидзе З.Г, Черткова А.И., Славина Е.Г. NKT-клетки и противоопухолевый иммунитет // Российский био-терапевтический журнал. - 2011. - Т. 10. - №3. - С. 9-15.
Моисеенко В.М., Балдуева И.А., Гельфонд М.Л. и соавт. Иммунотерапия костномозговыми предшественниками дендритных клеток, сенсибилизированных фотомодифицированными опухолевыми клетками in vivo, больных с диссеминированными солидными опухолями. - Медицинская технология, СПб., 2011. - 23 с.
Моисеенко В.М., Гельфонд М.Л., Балдуева И.А. и со-авт. Лечение диссеминированной меланомы вакциной на основе дендритных клеток, активированных опухолевыми клетками в состоянии фотоиндуцированного фотодитазином апоптоза // Рос. Биотер. Журнал. - 2009. - Т. 8. - № 2. - С. 37-38.
Bora C.R., Martinez L. Clinical development in dendritic cell based immunotherapy // J. Stem Cell Res. and Therap. - 2016. - Vol. 1. - Issue 2.
Dillman R. O., McClay E. F., Barth N. M. et al. Dendritic versus tumor cell presentation of autologous tumor antigens for active specific immunotherapy in metastatic melanoma: Impact on long-term survival by extent of disease at the time of treatment // Cancer Biother Radiopharm. - 2015. - Vol. 30. - Issue 5. - P187-194.
Dillman R.O., Nistor G.I., Cornforth A.N. Dendritic cell vaccines for melanoma: past, present and future // Melanoma Management - 2016. - Vol.3. - № 4. - P. 273-289.
Ellebaek E., Engell-Noerregaard L., Iversen T. Z. et al. Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: Results from a phase ii trial // Cancer Immunol Immunother. - 2012. - Vol. 61- Issue 10. - P 1791-1804.
Hanks B.A. Immune evasion pathways and the design of dendritic cell-based cancer vaccines // Discovery Med. -2016. - Published on February.
Korbelik M. PDT-associated host response and its role in the therapy outcome // Lasers surg Med. - 2006. - Vol. 38. - Issue 5. - P. 500-508.
Korbelik M., Stott B., Sun J. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression // Br J Cancer. - 2007. - Vol. 97 (10). - P. 13811387.
Lesterhuis W.L., de Vries J.M., Schreibelt G. et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients // Clin. Cancer Res. - 2016. - Vol. 17. - № 17. - P5725-5735.
Oshita C., Takikawa M., Kume A. et al. Dendritic cell-based vaccination in metastatic melanoma patients: Phase ii clinical trial // Oncol Rep. - 2012. - Vol. 28. -Issue 4. - P 1131-1138.
Radomski M., Zeh H.J., Edington H.D. et al. Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advance cancer // J. ImmonoTher. Cancer - 2016. - Vol. 4. - P. 24.
Ribas A., Camacho L. H., Lee S. M. et al. Multicenter phase ii study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma // J. Transl. Med. - 2010. - Vol. 8. - I. 89.
Ridolfi L., Petrini M., Fiammenghi L. et al. Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: Update of clinical outcome and subgroup analysis // Clin Dev Immunol. - 2010. - Vol. 2010. - I. 504979.
Robert C., Ribas A., Wolchok J. D. et al. Anti-programmed-death-receptor-1 treatment with pembroli-zumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial // Lancet. - 2014. - Vol. 384. - I. 9948. - P 11091117.
Sasse A. D., Sasse E. C., Clark L. G. et al. Chemoimmu-notherapy versus chemotherapy for metastatic malignant melanoma // Cochrane Database Syst Rev. - 2007. - Vol. 1. - P. CD005413.
Trepiakas R., Berntsen A., Hadrup S. R. et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: Results from a phase i/ii trial // Cytotherapy. - 2010. - Vol. 12. - I. 6. - P 721-734.
Tumeh P C., Harview C. L., Yearley J. H. et al. Pd-1 blockade induces responses by inhibiting adaptive immune resistance // Nature. - 2014. - Vol. 515. - I. 7528. - P 568-571.
Weber J. S., Kudchadkar R. R., Gibney G. T. et al. Phase i/ii trial of pd-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab // J. Clin. Oncol. - 2013. - Vol. 31. - abstr 9011.
Weber J. S., Kudchadkar R. R., Gibney G. T. et al. Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (ipi) // J. Clin. Oncol. - 2014. - Vol. 32. - abstr 3009.
Zheng Y, Yin G., Le V. et al. Photodynamic-therapy Activates Immune Response by disrupting Immunity Homeostasis of Tumor Cells, which Generates Vaccine for Cancer Therapy // Int. J. Biol. Sci. - 2016. -Vol. 12 (1). - P. 120-132.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017